CD36: a key mediator of resistance to HER2 inhibitors in breast cancer. (3rd March 2020)
- Record Type:
- Journal Article
- Title:
- CD36: a key mediator of resistance to HER2 inhibitors in breast cancer. (3rd March 2020)
- Main Title:
- CD36: a key mediator of resistance to HER2 inhibitors in breast cancer
- Authors:
- Feng, William W.
Bang, Scott
Kurokawa, Manabu - Abstract:
- ABSTRACT: Acquired resistance to anti-HER2 therapy is a significant clinical challenge in breast cancer. We recently discovered that during acquisition of resistance to HER2 inhibition, upregulation of the fatty acid transporter CD36 takes place, playing a key role in metabolic rewiring and resistance to anti-HER2 therapy.
- Is Part Of:
- Molecular & cellular oncology. Volume 7:Number 2(2020)
- Journal:
- Molecular & cellular oncology
- Issue:
- Volume 7:Number 2(2020)
- Issue Display:
- Volume 7, Issue 2 (2020)
- Year:
- 2020
- Volume:
- 7
- Issue:
- 2
- Issue Sort Value:
- 2020-0007-0002-0000
- Page Start:
- Page End:
- Publication Date:
- 2020-03-03
- Subjects:
- FASN -- FATP -- lapatinib -- lipid metabolism -- trastuzumab
Tumors -- Periodicals
Neoplasms
Periodicals
616.99 - Journal URLs:
- http://www.tandfonline.com/loi/kmco20#.VyIIeFL2aic ↗
http://www.tandfonline.com/ ↗ - DOI:
- 10.1080/23723556.2020.1715766 ↗
- Languages:
- English
- ISSNs:
- 2372-3556
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12949.xml